Homology Medicines Inc (NASDAQ:FIXX) Insider Sells $23,250.04 in Stock

Homology Medicines Inc (NASDAQ:FIXX) insider Timothy P. Kelly sold 1,166 shares of the firm’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $19.94, for a total transaction of $23,250.04.

Homology Medicines stock opened at $20.48 on Friday. The stock has a market capitalization of $954.07 million, a PE ratio of -10.24 and a beta of 0.11. Homology Medicines Inc has a twelve month low of $14.19 and a twelve month high of $31.80. The company has a 50 day moving average of $18.02 and a 200-day moving average of $21.60.

Homology Medicines (NASDAQ:FIXX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.06). Homology Medicines had a negative return on equity of 38.74% and a negative net margin of 3,232.67%. The firm had revenue of $0.39 million for the quarter, compared to the consensus estimate of $1.00 million. On average, equities research analysts forecast that Homology Medicines Inc will post -2.27 EPS for the current fiscal year.

Several research analysts recently commented on FIXX shares. HC Wainwright set a $36.00 target price on shares of Homology Medicines and gave the stock a “buy” rating in a report on Tuesday, June 11th. Zacks Investment Research upgraded shares of Homology Medicines from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Canaccord Genuity set a $37.00 target price on shares of Homology Medicines and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Robert W. Baird started coverage on shares of Homology Medicines in a research report on Monday. They issued an “outperform” rating and a $30.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Homology Medicines presently has an average rating of “Buy” and an average target price of $31.40.

Several institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new stake in Homology Medicines during the first quarter worth about $2,582,000. BNP Paribas Arbitrage SA bought a new stake in shares of Homology Medicines in the 1st quarter valued at $99,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new stake in shares of Homology Medicines in the 2nd quarter valued at $105,000. JPMorgan Chase & Co. grew its position in Homology Medicines by 1.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,006,682 shares of the company’s stock valued at $38,748,000 after purchasing an additional 25,312 shares during the period. Finally, Aperio Group LLC acquired a new stake in Homology Medicines in the 2nd quarter valued at $34,000. 68.09% of the stock is currently owned by institutional investors.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Read More: Google Finance

Insider Buying and Selling by Quarter for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.